Cargando…

Pharmacokinetics, Efficacy and Safety of a Plasma-Derived VWF/FVIII Concentrate (Formulation V) in Pediatric Patients with von Willebrand Disease (SWIFTLY-VWD Study)

PURPOSE: Formulation V (VONCENTO(®)) is a plasma-derived high-concentration/low-volume, high-purity von Willebrand factor (VWF)/factor VIII (FVIII) concentrate, originally indicated for von Willebrand disease (VWD) in adults and adolescents. This multicenter, open-label study (SWIFTLY-VWD) evaluated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Auerswald, Guenter, Djambas Khayat, Claudia, Stasyshyn, Oleksandra, Iosava, Genadi, Romashevskaya, Irina, López, Marta Julia, Seifert, Wilfried, Rogosch, Tobias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319533/ https://www.ncbi.nlm.nih.gov/pubmed/32607039 http://dx.doi.org/10.2147/JBM.S236789

Ejemplares similares

Efficacy, Safety and Pharmacokinetic Results of a Phase III, Open-Label, Multicenter Study with a Plasma-Derived Von Willebrand Factor (VWF)/Factor VIII (FVIII) Concentrate in Pediatric Patients <12 Years of Age with Hemophilia A (SWIFTLY-HA Study)
por: Djambas Khayat, Claudia, et al.
Publicado: (2021)

An Open-Label Extension Study to Assess the Long-Term Efficacy and Safety of a Plasma-Derived von Willebrand Factor (VWF)/Factor VIII (FVIII) Concentrate in Patients with von Willebrand Disease (SWIFT-VWDext Study)
por: Lissitchkov, Toshko, et al.
Publicado: (2020)

Pharmacokinetics, efficacy, and safety of a plasma-derived VWF/FVIII concentrate (VONCENTO) for on-demand and prophylactic treatment in patients with von Willebrand disease (SWIFT-VWD study)
por: Lissitchkov, Toshko J., et al.
Publicado: (2017)

Common VWF sequence variants associated with higher VWF and FVIII are less frequent in subjects diagnosed with type 1 VWD
por: Flood, Veronica H., et al.
Publicado: (2018)

Role of multimeric analysis of von Willebrand factor (VWF) in von Willebrand disease (VWD) diagnosis: Lessons from the PCM-EVW-ES Spanish project
por: Pérez-Rodríguez, Almudena, et al.
Publicado: (2018)

BMI is an important determinant of VWF and FVIII levels and bleeding phenotype in patients with von Willebrand disease
por: Atiq, Ferdows, et al.
Publicado: (2019)

The VWF binding aptamer rondoraptivon pegol increases platelet counts and VWF/FVIII in type 2B von Willebrand disease
por: Ay, Cihan, et al.
Publicado: (2022)

Effectiveness of long‐term prophylaxis using pdFVIII/VWF concentrate in patients with inherited von Willebrand disease
por: Rugeri, Lucia, et al.
Publicado: (2022)

Comorbidities associated with higher von Willebrand factor (VWF) levels may explain the age‐related increase of VWF in von Willebrand disease
por: Atiq, Ferdows, et al.
Publicado: (2018)

Continuous Infusion of Factor VIII and von Willebrand Factor in Surgery: Trials with pdFVIII LFB or pdVWF LFB in Patients with Bleeding Disorders
por: Windyga, Jerzy, et al.
Publicado: (2022)

Utility of a high VWF:FVIII ratio in preventing FVIII accumulation: a study in VWF-deficient mice
por: Raquet, Elmar, et al.
Publicado: (2015)

Dental invasive procedures in von Willebrand disease outpatients treated with high purity FVIII/VWF complex concentrate (Fanhdi®): experience of a single center
por: De Padua, Valeria, et al.
Publicado: (2020)

Native plasma-derived FVIII/VWF complex has lower sensitivity to FVIII inhibitors than the combination of isolated FVIII and VWF proteins. Impact on Bethesda assay titration of FVIII inhibitors
por: Bravo, M I, et al.
Publicado: (2014)

In Vitro Assessment of von Willebrand Factor in Cryoprecipitate, Antihemophilic Factor/VWF Complex (Human), and Recombinant von Willebrand Factor
por: Colling, Meaghan E., et al.
Publicado: (2019)

von Willebrand disease with G4022A mutation (vWd Sungnam): a case report.
por: Song, K. S., et al.
Publicado: (1999)

Multifaceted pathomolecular mechanism of a VWF large deletion involved in the pathogenesis of severe VWD
por: Yadegari, Hamideh, et al.
Publicado: (2022)

A rat model of severe VWD by elimination of the VWF gene using CRISPR/Cas9
por: Garcia, Jessica, et al.
Publicado: (2019)

Von Willebrand disease type 2B with a novel mutation in the VWF gene
por: Jeraiby, Mohammed Abdullah, et al.
Publicado: (2021)

The development and characterization of a long acting anti‐thrombotic von Willebrand factor (VWF) aptamer
por: Zhu, Shuhao, et al.
Publicado: (2020)

von Willebrand factor antigen levels are associated with burden of rare nonsynonymous variants in the VWF gene
por: Sadler, Brooke, et al.
Publicado: (2021)

The aptamer BT200 effectively inhibits von Willebrand factor (VWF) dependent platelet function after stimulated VWF release by desmopressin or endotoxin
por: Kovacevic, Katarina D., et al.
Publicado: (2020)

Laboratory assays of VWF activity and use of desmopressin trials in the diagnosis of VWD: a systematic review and meta-analysis
por: Kalot, Mohamad A., et al.
Publicado: (2022)

Von Willebrand Factor Abnormalities Studied in the Mouse Model: What We Learned about VWF Functions
por: Casari, Caterina, et al.
Publicado: (2013)

von Willebrand factor promotes platelet-induced metastasis of osteosarcoma through activation of the VWF-GPIb axis
por: Wang, Q., et al.
Publicado: (2020)

Human plasma-derived FVIII/VWD concentrate (Biostate): a review of experimental and clinical pharmacokinetic, efficacy and safety data
por: Harper, Paul, et al.
Publicado: (2016)

Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery
por: Peyvandi, F., et al.
Publicado: (2018)

The role of VWF/FVIII in thrombosis and cancer progression in multiple myeloma and other hematological malignancies
por: Comerford, Claire, et al.
Publicado: (2022)

A transcriptome analysis of basal and stimulated VWF release from endothelial cells derived from patients with type 1 VWD
por: Kloosterman, Robert, et al.
Publicado: (2022)

A 12.3-kb Duplication Within the VWF Gene in Pigs Affected by Von Willebrand Disease Type 3
por: Lehner, Stefanie, et al.
Publicado: (2017)

The Flow Dependent Adhesion of von Willebrand Factor (VWF)-A1 Functionalized Nanoparticles in an in Vitro Coronary Stenosis Model
por: Asaad, Yathreb, et al.
Publicado: (2019)

Combined analysis of three genome-wide association studies on vWF and FVIII plasma levels
por: Antoni, Guillemette, et al.
Publicado: (2011)

Phenotypic and Genotypic Signatures of VWF Exon 18 in Eastern Saudi Patients Previously Diagnosed with Type 1 von Willebrand Disease
por: Alzahrani, Faisal M, et al.
Publicado: (2022)

Plasma‐derived FVIII/VWF complex shows higher protection against inhibitors than isolated FVIII after infusion in haemophilic patients: A translational study
por: Bravo, Maria Isabel, et al.
Publicado: (2022)

Effects of Shear Stress on Production of FVIII and vWF in a Cell-Based Therapeutic for Hemophilia A
por: Trevisan, Brady, et al.
Publicado: (2021)

One piece of the puzzle: Population pharmacokinetics of FVIII during perioperative Haemate P(®)/Humate P(®) treatment in von Willebrand disease patients
por: de Jager, Nico C. B., et al.
Publicado: (2019)

Immunohistochemial study on the expression of von Willebrand factor (vWF) after onlay autogenous iliac grafts for lateral alveolar ridge augmentation
por: Koerdt, Steffen, et al.
Publicado: (2013)

Von Willebrand factor (vWF) in patients with heart failure with preserved ejection fraction (HFpEF): A retrospective observational study
por: Abudoukelimu, Mayila, et al.
Publicado: (2022)

Hemophilia and von Willebrand disease: Factor VIII and von Willebrand factor
por: Sharma, Prashant
Publicado: (2019)

Clinical Efficacy and Safety of Fanhdi(®), a Plasma-Derived VWF/Factor VIII Concentrate, in von Willebrand Disease in Spain: A Retrospective Study
por: Jiménez-Yuste, Víctor, et al.
Publicado: (2022)

A p.Arg127Gln variant in GPIbα LRR5 allosterically enhances affinity for VWF: a novel form of platelet-type VWD
por: Bury, Loredana, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q3hbcdj7gj118im2mnvcsnknn1